Handelsavisen
prelaunch
Companies Healthcare 4129.TWO
41
4129.TWO TPEx Medical Equipment, Supplies & Distribution

4129.Two

$93,20
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
4,07 %
Op margin
13,1 %
ROE
13,7 %
Net margin
9,9 %
Debt / equity
0,50
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.

Business. 4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target141,50

Analyst recommendations

4 analysts · consensus Buy
Buy4
Hold0
Sell0
12-month price target
141,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
4 analysts · indicative
Ownership
not yet wired
Profitability
13,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4129.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4129.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    4129.TWO is a medical equipment and supplies company operating in the healthcare services and equipment sector, generating revenue primarily through the distribution and sale of medical products.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.5, indicating a relatively balanced mix of debt and equity financing. Its liquidity position is assessed as medium, with a current ratio of 1.72, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's free cash flow is negative at -36,886,000 TWD, which may indicate that the company is investing heavily in its operations or facing operational inefficiencies.

    In terms of profitability, the company's return on equity (ROE) is 13.72%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets (ROA) is 7.19%, indicating that the company is generating a moderate return on its total assets. These figures should be compared against the industry's preferred metrics and cohort medians to determine if the company is outperforming or underperforming its peers.

    The company's revenue concentration is not explicitly detailed in the provided data, but the absence of segment-specific revenue data suggests that the company may not have a significant geographic or product diversification. This could pose a risk if the company is overly reliant on a single market or product line.

    The company's growth trajectory is not explicitly outlined in the provided data, but the absence of a detailed outlook and the negative free cash flow may suggest that the company is in a phase of investment or facing challenges in generating positive cash flow from operations. The company's capital expenditure of -761,231,000 TWD indicates a significant investment in long-term assets, which could be a sign of expansion or modernization efforts.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares that could dilute existing shareholders' equity.

    Recent events, such as analyst estimates and recommendations, suggest a positive outlook from the investment community. The mean price target is 141.50 TWD, with a median price target of 141.50 TWD, and a mean recommendation of 1.50, indicating a generally positive sentiment towards the company. The absence of recent filings or transcripts does not provide additional insight into the company's recent activities or strategic direction.

    Key takeaways
    • The company has a balanced capital structure with a debt-to-equity ratio of 0.5.
    • The company's ROE of 13.72% indicates strong profitability relative to shareholders' equity.
    • The company's liquidity position is medium, with a current ratio of 1.72.
    • The company's free cash flow is negative, which may indicate significant investment in operations or inefficiencies.
    • The company's growth trajectory is not clearly defined, but the negative free cash flow and significant capital expenditure suggest investment or expansion efforts.
    • The investment community has a generally positive outlook, with a mean price target of 141.50 TWD and a mean recommendation of 1.50.
    • margin_outlook_rationale: The company's gross profit margin is strong, but the operating margin is moderate, suggesting potential for improvement in cost management.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $93,20
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.10B
    Net cash
    -$1.90B
    Current ratio
    1.7
    Debt / equity
    0.5
    ROA
    7.2%
    ROE
    13.7%
    Cash conversion
    182.0%
    CapEx / revenue
    -13.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    6,98
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    4
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate6,98
    Revenueno estimateno estimate6,7B TWD
    Operating incomeno estimateno estimate912,2M TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution4 analysts
    Strong buy2
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$141,50 · Median $141,50
    Low $141,00High $142,00
    Operating income · consensus912,2M TWD
    EPS surprise
    −18,8 %
    reported vs consensus · miss
    Revenue surprise
    −15,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$141,00
    Mean$141,50
    Median$141,50
    High$142,00
    Spot$93,20
    +51.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,1 %Above median
    Net Margin10,0 %Above median
    ROE13,7 %Above P75
    Capex / Rev-13,5 %Bottom quartile
    D/E0,50Below median
    Cash Conv1,82Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 4129.TWO Market data — financials · 2026-05-26
    • United Orthopedic Corp Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4129.TWOCanonical
    TPEx · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage